NO302998B1 - Mikrokuler, fremgangsmÕte for fremstilling samt anvendelse av slike ved fremstilling av et preparat - Google Patents
Mikrokuler, fremgangsmÕte for fremstilling samt anvendelse av slike ved fremstilling av et preparat Download PDFInfo
- Publication number
- NO302998B1 NO302998B1 NO924792A NO924792A NO302998B1 NO 302998 B1 NO302998 B1 NO 302998B1 NO 924792 A NO924792 A NO 924792A NO 924792 A NO924792 A NO 924792A NO 302998 B1 NO302998 B1 NO 302998B1
- Authority
- NO
- Norway
- Prior art keywords
- microspheres
- substance
- progesterone
- diameter
- microspheres according
- Prior art date
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 91
- 238000000034 method Methods 0.000 title claims description 18
- 238000002360 preparation method Methods 0.000 title claims description 17
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims abstract description 48
- 229960003387 progesterone Drugs 0.000 claims abstract description 24
- 239000000186 progesterone Substances 0.000 claims abstract description 24
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims abstract description 19
- 229960005309 estradiol Drugs 0.000 claims abstract description 18
- 238000002844 melting Methods 0.000 claims abstract description 16
- 230000008018 melting Effects 0.000 claims abstract description 16
- 239000000725 suspension Substances 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 239000007787 solid Substances 0.000 claims abstract description 10
- 239000003921 oil Substances 0.000 claims abstract description 7
- 239000000654 additive Substances 0.000 claims abstract description 5
- 239000003433 contraceptive agent Substances 0.000 claims abstract description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 3
- 238000009472 formulation Methods 0.000 claims abstract 5
- 239000002245 particle Substances 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 238000007710 freezing Methods 0.000 claims description 9
- 230000008014 freezing Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 239000012298 atmosphere Substances 0.000 claims description 6
- 230000000144 pharmacologic effect Effects 0.000 claims description 6
- 238000000889 atomisation Methods 0.000 claims description 5
- 239000003595 mist Substances 0.000 claims description 5
- 239000003838 injectable contraceptive agent Substances 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 230000004720 fertilization Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 230000003509 anti-fertility effect Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000002254 contraceptive effect Effects 0.000 abstract description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 abstract description 4
- 238000005507 spraying Methods 0.000 abstract description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 abstract description 2
- 229960000905 indomethacin Drugs 0.000 abstract description 2
- 229960002009 naproxen Drugs 0.000 abstract description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000011261 inert gas Substances 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 239000000155 melt Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 23
- 239000013078 crystal Substances 0.000 description 18
- 239000013543 active substance Substances 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 6
- 239000007900 aqueous suspension Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940107161 cholesterol Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 238000002663 nebulization Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940088623 biologically active substance Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000002060 circadian Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9007416A FR2663223B1 (fr) | 1990-06-14 | 1990-06-14 | Forme galenique parenterale. |
| PCT/EP1991/001096 WO1991019484A1 (fr) | 1990-06-14 | 1991-06-12 | Composition pharmaceutique injectable |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO924792D0 NO924792D0 (no) | 1992-12-11 |
| NO924792L NO924792L (no) | 1993-02-03 |
| NO302998B1 true NO302998B1 (no) | 1998-05-18 |
Family
ID=9397598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO924792A NO302998B1 (no) | 1990-06-14 | 1992-12-11 | Mikrokuler, fremgangsmÕte for fremstilling samt anvendelse av slike ved fremstilling av et preparat |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US5360616A (de) |
| EP (1) | EP0533739B1 (de) |
| JP (1) | JP2675675B2 (de) |
| KR (1) | KR0157439B1 (de) |
| CN (1) | CN1057442C (de) |
| AT (1) | ATE109658T1 (de) |
| AU (1) | AU661275B2 (de) |
| BG (1) | BG61179B1 (de) |
| BR (1) | BR9106545A (de) |
| CA (1) | CA2085344C (de) |
| CZ (1) | CZ286793B6 (de) |
| DE (1) | DE69103419T2 (de) |
| DK (1) | DK0533739T3 (de) |
| ES (1) | ES2059142T3 (de) |
| FI (1) | FI107698B (de) |
| FR (1) | FR2663223B1 (de) |
| HU (1) | HUT68709A (de) |
| IE (1) | IE62679B1 (de) |
| IL (1) | IL98459A (de) |
| NO (1) | NO302998B1 (de) |
| NZ (1) | NZ238542A (de) |
| PL (1) | PL167234B1 (de) |
| PT (1) | PT97975B (de) |
| RU (1) | RU2104692C1 (de) |
| SK (1) | SK280564B6 (de) |
| TN (1) | TNSN91048A1 (de) |
| UA (1) | UA27043C2 (de) |
| UY (1) | UY23240A1 (de) |
| WO (1) | WO1991019484A1 (de) |
| ZA (1) | ZA914550B (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2663224B1 (fr) * | 1990-06-14 | 1995-01-20 | Applicationes Farmaceuticas Sa | Forme galenique parenterale. |
| GB9313642D0 (en) * | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| FR2732621B1 (fr) * | 1995-04-10 | 1997-06-06 | Rhone Poulenc Chimie | Perles d'un produit presentant le phenomene de surfusion et leur procede d'obtention |
| US5904935A (en) * | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
| US6028057A (en) * | 1998-02-19 | 2000-02-22 | Thorn Bioscience, Llc | Regulation of estrus and ovulation in gilts |
| ATE265846T1 (de) * | 1998-02-25 | 2004-05-15 | Abbott Lab | Butorphanol enthaltende formulierungen mit verzögerter freisetzung |
| US6287693B1 (en) | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| CA2382216A1 (en) * | 1999-08-20 | 2001-03-01 | Xian Ming Zeng | Method to produce powders for pulmonary or nasal administration |
| US20030055075A1 (en) * | 2001-07-13 | 2003-03-20 | Rubsamen Reid M. | Programmable controlled release injectable opioid formulation |
| US20070254008A1 (en) * | 2001-07-13 | 2007-11-01 | Flow Focusing, Inc. | Antibiotic formulation and method of treatment |
| US20070254009A1 (en) * | 2001-07-13 | 2007-11-01 | Flow Focusing, Inc. | Antibiotic/bone morphogenic protein formulation and method of treatment |
| GB0117696D0 (en) * | 2001-07-20 | 2001-09-12 | Bradford Particle Design Plc | Particle information |
| AU2004246870B2 (en) | 2003-06-13 | 2009-07-23 | Skendi Finance Ltd | Slow release estradiol-progesterone formulation for contraception and hormone replacement therapy |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| US9532995B2 (en) | 2003-09-03 | 2017-01-03 | Miscon Trading S.A. | Methods for the treatment of endometriosis |
| US7205281B2 (en) | 2003-10-03 | 2007-04-17 | Thorn Bioscience, Llc | Process for the synchronization of ovulation for timed breeding without heat detection |
| BRPI0415531B8 (pt) | 2003-10-23 | 2021-05-25 | Otsuka Pharma Co Ltd | formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação |
| US7413690B1 (en) | 2003-10-29 | 2008-08-19 | The University Of Mississippi | Process and apparatus for producing spherical pellets using molten solid matrices |
| US7491263B2 (en) * | 2004-04-05 | 2009-02-17 | Technology Innovation, Llc | Storage assembly |
| US7392635B2 (en) * | 2005-06-09 | 2008-07-01 | Tipper Tie, Inc. | Breech loader packaging systems and associated breech loading chutes and methods |
| US20070197435A1 (en) * | 2006-02-17 | 2007-08-23 | Webel Stephen K | Process for the synchronization of ovulation for timed breeding without heat detection |
| ATE475686T1 (de) | 2006-10-31 | 2010-08-15 | Surmodics Pharmaceuticals Inc | Kugelförmige polymer-teilchen |
| AR067747A1 (es) | 2007-07-31 | 2009-10-21 | Otsuka Pharma Co Ltd | Metodos para producir suspension de aripiprazol y formulacion liofilizada |
| CN102056611A (zh) * | 2008-04-14 | 2011-05-11 | Posi维森纳里解决方案有限责任公司 | 用于获得不同的治疗适应症所需要的血浆孕酮水平的方法和药物组合物 |
| WO2010124220A1 (en) | 2009-04-23 | 2010-10-28 | Pennatek, Llc | Method and composition for synchronizing time of insemination |
| UY33103A (es) * | 2009-12-15 | 2011-07-29 | Techsphere S A De C V | Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico |
| CN113398243A (zh) | 2012-11-28 | 2021-09-17 | 联合动物健康第二有限责任公司 | 用于同步小母猪的授精时间的方法 |
| WO2017105512A1 (en) | 2015-12-18 | 2017-06-22 | Proinvet Innovations S.A. | Formulations and methods for controlling the reproductive cycle and ovulation |
| CA3015781C (en) * | 2016-02-24 | 2024-04-23 | Eastern Virginia Medical School | An improved formulation of long-acting levonorgestrel butanoate injectable depot suspension |
| CN106063783B (zh) * | 2016-06-16 | 2019-03-12 | 浙江爱生药业有限公司 | 一种黄体酮缓释微囊制剂及其制备方法 |
| US11376220B2 (en) | 2017-06-30 | 2022-07-05 | Therio, LLC | Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals |
| CN115212170B (zh) * | 2021-04-19 | 2024-01-26 | 中国人民解放军军事科学院军事医学研究院 | 一种致密圆整的药物球形微晶及其制备方法和其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE670438A (de) * | 1964-10-06 | 1966-01-31 | ||
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3928566A (en) * | 1970-08-14 | 1975-12-23 | Du Pont | Lyophilized biological products |
| JPS5017525A (de) * | 1973-06-14 | 1975-02-24 | ||
| CA1077842A (en) * | 1975-10-09 | 1980-05-20 | Minnesota Mining And Manufacturing Company | Albumin medicament carrier system |
| US4244949A (en) * | 1978-04-06 | 1981-01-13 | The Population Council, Inc. | Manufacture of long term contraceptive implant |
| US4349580A (en) * | 1978-08-18 | 1982-09-14 | Queen's University At Kingston | Process and solution for preserving green plant tissues |
| US4384975A (en) * | 1980-06-13 | 1983-05-24 | Sandoz, Inc. | Process for preparation of microspheres |
| US4349530A (en) * | 1980-12-11 | 1982-09-14 | The Ohio State University | Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal |
| US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| IL79407A (en) * | 1985-08-01 | 1991-03-10 | Theragenics Corp | System and method for delivering insoluble material into a living body |
| US4837381A (en) * | 1986-08-11 | 1989-06-06 | American Cyanamid Company | Compositions for parenteral administration and their use |
| ES2039219T3 (es) * | 1986-08-11 | 1993-09-16 | American Cyanamid Company | Composiciones para administracion parenteral y su uso. |
| US4892734A (en) * | 1987-04-06 | 1990-01-09 | Endocon, Inc. | Dispensing paste for forming medicinal pellets |
| ATE109941T1 (de) * | 1987-04-06 | 1994-09-15 | Endocon Inc | Durch schnellschmelzen hergestellte medizinische implantate. |
| US4748024A (en) * | 1987-04-06 | 1988-05-31 | Endocon, Inc. | Flash flow fused medicinal implants |
| CA2030551C (en) * | 1989-05-01 | 1998-08-25 | Wayne Gombotz | Process for producing small particles of biologically active molecules |
| US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
-
1990
- 1990-06-14 FR FR9007416A patent/FR2663223B1/fr not_active Expired - Fee Related
-
1991
- 1991-06-11 IL IL9845991A patent/IL98459A/en not_active IP Right Cessation
- 1991-06-12 JP JP3510331A patent/JP2675675B2/ja not_active Expired - Lifetime
- 1991-06-12 AT AT91910762T patent/ATE109658T1/de not_active IP Right Cessation
- 1991-06-12 AU AU80847/91A patent/AU661275B2/en not_active Ceased
- 1991-06-12 ES ES91910762T patent/ES2059142T3/es not_active Expired - Lifetime
- 1991-06-12 RU RU92016471A patent/RU2104692C1/ru active
- 1991-06-12 CA CA002085344A patent/CA2085344C/en not_active Expired - Fee Related
- 1991-06-12 DE DE69103419T patent/DE69103419T2/de not_active Expired - Fee Related
- 1991-06-12 EP EP91910762A patent/EP0533739B1/de not_active Expired - Lifetime
- 1991-06-12 DK DK91910762.3T patent/DK0533739T3/da active
- 1991-06-12 HU HU9203958A patent/HUT68709A/hu unknown
- 1991-06-12 WO PCT/EP1991/001096 patent/WO1991019484A1/fr active IP Right Grant
- 1991-06-12 UA UA93004686A patent/UA27043C2/uk unknown
- 1991-06-12 KR KR1019920703205A patent/KR0157439B1/ko not_active IP Right Cessation
- 1991-06-12 BR BR919106545A patent/BR9106545A/pt not_active Application Discontinuation
- 1991-06-13 CZ CS19911816A patent/CZ286793B6/cs not_active IP Right Cessation
- 1991-06-13 IE IE201791A patent/IE62679B1/en not_active IP Right Cessation
- 1991-06-13 US US07/714,583 patent/US5360616A/en not_active Expired - Lifetime
- 1991-06-13 UY UY23240A patent/UY23240A1/es not_active IP Right Cessation
- 1991-06-13 SK SK1816-91A patent/SK280564B6/sk unknown
- 1991-06-14 PL PL91290677A patent/PL167234B1/pl not_active IP Right Cessation
- 1991-06-14 PT PT97975A patent/PT97975B/pt not_active IP Right Cessation
- 1991-06-14 TN TNTNSN91048A patent/TNSN91048A1/fr unknown
- 1991-06-14 CN CN91104859A patent/CN1057442C/zh not_active Expired - Fee Related
- 1991-06-14 NZ NZ238542A patent/NZ238542A/xx not_active IP Right Cessation
- 1991-06-14 ZA ZA914550A patent/ZA914550B/xx unknown
-
1992
- 1992-12-11 FI FI925661A patent/FI107698B/fi active
- 1992-12-11 NO NO924792A patent/NO302998B1/no not_active IP Right Cessation
- 1992-12-14 BG BG97166A patent/BG61179B1/bg unknown
-
1994
- 1994-05-17 US US08/243,823 patent/US5512303A/en not_active Expired - Lifetime
-
1996
- 1996-04-15 US US08/632,616 patent/US5633014A/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO302998B1 (no) | Mikrokuler, fremgangsmÕte for fremstilling samt anvendelse av slike ved fremstilling av et preparat | |
| US5643604A (en) | Parenteral dosage form | |
| JP4885357B2 (ja) | 結晶性有機化合物の安定な成形粒子 | |
| WO2003088951A1 (en) | Formulation of fine particles using liquefied or dense gases | |
| CN110740724A (zh) | 无定形的纳米结构药物材料 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN DECEMBER 2003 |